

Electronic Supplementary Information for

Redox-active benzimidazolium sulfonamides as cationic thiolating reagent for reductive cross-coupling of organic halides

Weigang Zhang, Mengjun Huang, Zhenlei Zou, Zhengguang Wu, Shengyang Ni, Lingyu Kong, Youxuan Zheng, Yi Wang* and Yi Pan

State Key Laboratory of Coordination Chemistry, Jiangsu Key Laboratory of Advanced Organic Materials, and Collaborative Innovation Center of Advanced Microstructures, School of Chemistry and Chemical Engineering, Nanjing University, Nanjing 210023, China

Table of Contents

I. General Methods	3
II. Synthesis of Starting Materials	4
III. Synthesis of Imidazolium Sulfonamides (1a-1n)	4
IV. General Procedures	9
V. Mechanistic Studies	9
VI. Characteristic Data	12
VII. NMR Spectra for Compounds	34
VIII. References	115

I. General Methods

All reactions were performed in flame-dried glassware with magnetic stirring bar and sealed with a rubber septum. The solvents were distilled by standard methods. Reagents were obtained from commercial suppliers and used without further purification unless otherwise noted. Silica gel column chromatography was carried out using silica Gel 60 (230–400 mesh). Analytical thin layer chromatography (TLC) was done using silica Gel (silica gel 60 F254). TLC plates were analyzed by an exposure to ultraviolet (UV) light and/or submersion in phosphomolybdic acid solution or submersion in KMnO₄ solution or in I₂. NMR experiments were measured on a Bruker AVANCE III-400 or 500 spectrometer and carried out in chloroform-*d* (CDCl₃) or acetonitrile-*d*₃ (CD₃CN). ¹H NMR and ¹³C NMR spectra were recorded at 400 MHz or 500 MHz and 100 MHz or 125 MHz spectrometers, respectively. ¹⁹F NMR spectra were recorded at 376 MHz or 470 MHz spectrometers. Chemical shifts are reported as δ values relative to internal TMS (δ 0.00 for ¹H NMR), chloroform (δ 7.26 for ¹H NMR), acetonitrile (δ 1.94 for ¹H NMR), chloroform (δ 77.00 for ¹³C NMR), and acetonitrile (δ 1.32 or 118.26 for ¹³C NMR) in parts per million (ppm). The following abbreviations are used for the multiplicities: s: singlet, d: doublet, dd: doublet of doublet, t: triplet, q: quadruplet, m: multiplet, br: broad signal for proton spectra; Coupling constants (*J*) are reported in Hertz (Hz). Melting points were uncorrected. Infrared spectra were obtained on agilent Cary630. HRMS were recorded on a Bruker miccOTOF-Q111. GC-MS spectra were performed on Agilent 5977B.

Medium-sized screw-cap test tubes (8 mL) were used for all 0.20 mmol scale reactions: Fisher 13 x 100 mm tubes (Cat. No.1495935C)




Cap with Septa: Thermo Scientific ASM PHN CAP w/PTFE/SIL (Cat. No.03378316)



II. Synthesis of Starting Materials


Unless otherwise noted, all halides were purchased from commercial source. Starting materials of products **10a-10d** were prepared according to the literature^{1a}.

III. Synthesis of Imidazolium Sulfonamides (**1a-1n**)




- 1) To a one-necked 100 mL flask equipped with a magnetic stirrer, the corresponding imidazole (10 mmol), NEt₃ (150 mmol) and 40 mL DCM were added. The flask was then cooled in a ice bath, and about 13 mmol corresponding arylsulfonyl chloride was added into it slowly. Then, The mixture was stirred at room temperature for 2 hours. After the reaction was completed by TLC monitoring, the reaction mixture was evaporated in vacuo. Then, the reaction mixture was quenched with water and extracted with ethyl acetate (60 mL × 3). The combined organic layers were dried over Na₂SO₄, filtered and concentrated. The product was purified by flash column chromatography on silica gel with *n*-pentane/ethyl acetate as eluent to give the corresponding intermediate **A**.
- 2) Under argon, to a solution of the corresponding intermediate **A** in dried DCM (40 mL) was added dropwise MeOTf (13 mmol) at 0 °C. Then, the mixture was stirred at room temperature for 12 hours, while monitoring by TLC. After that time, the mixture was concentrated under rotary evaporation to give a white solid (or a viscous liquid) crude product, to which Et₂O (30 mL) was added. With vigorous stirring, a solid precipitate was formed. The precipitate was washed with Et₂O (30 mL × 3) and dried in vacuo to yield the title compound (**1a-1n**) as a white solid.

2,3-dimethyl-1-tosyl-1*H*-benzo[*d*]imidazol-3-ium trifluoromethanesulfonate (1a**)**




1597.2, 1559.9, 1463.0, 1388.4, 1258.0, 1144.3, 1086.5, 1028.7, 961.7, 892.7, 810.7, 752.9, 635.5; HRMS (ESI): calcd for $C_{16}H_{17}N_2O_2S^+ [M]^+$ 301.1005; found 301.1009.


3-methyl-2-phenyl-1-tosyl-1*H*-imidazol-3-i^{um} trifluoromethanesulfonate (1b)

 82%; white solid; 1H NMR (400 MHz, $CDCl_3$) δ 8.00 (d, $J = 2.3$ Hz, 1H), 7.82 (d, $J = 2.3$ Hz, 1H), 7.72 – 7.67 (m, 1H), 7.54 – 7.49 (m, 2H), 7.39 – 7.32 (m, 4H), 7.24 – 7.20 (m, 2H), 3.72 (s, 4H), 2.42 (s, 4H). ^{13}C NMR (101 MHz, $CDCl_3$) δ 148.9, 145.3, 133.1, 131.0, 130.5, 130.4, 129.1, 129.0, 124.1, 120.6 (q, $J = 320.6$ Hz), 120.4, 119.5, 36.6, 21.8. ^{19}F NMR (377 MHz, $CDCl_3$) δ -78.36. IR (neat) ν (cm^{-1}): 3183.1, 3123.5, 3067.6, 1587.8, 1442.5, 1405.2, 1254.2, 1153.6, 1026.9, 984.0, 810.7, 769.7, 633.6, 538.6; HRMS (ESI): calcd for $C_{17}H_{17}N_2O_2S^+ [M]^+$ 313.1005; found 313.1012.

2,3-dimethyl-1-((4-(trifluoromethoxy)phenyl)sulfonyl)-1*H*-benzo[*d*]imidazol-3-i^{um} trifluoromethanesulfonate (1c)


 93%; white solid; 1H NMR (400 MHz, CD_3CN) δ 8.36 – 8.32 (m, 3H), 7.88 – 7.72 (m, 3H), 7.60 – 7.56 (m, 2H), 3.96 (s, 3H), 3.10 (s, 3H). ^{13}C NMR (101 MHz, CD_3CN) δ 155.86 (s), 155.35 (s), 134.22 (s), 132.61 (s), 132.49 (s), 129.9, 129.8, 129.1, 123.1, 122.1 (q, $J = 320.7$ Hz), 121.1 (q, $J = 259.2$ Hz), 116.0, 114.6, 33.6, 13.9. ^{19}F NMR (377 MHz, CD_3CN) δ -58.51, -79.31. IR (neat) ν (cm^{-1}): 3116.1, 1589.7, 1466.7, 1410.8, 1261.7, 1161.1, 1028.7, 965.4, 896.4, 758.5, 572.1, 516.2; HRMS (ESI): calcd for $C_{16}H_{14}F_3N_2O_3S^+ [M]^+$ 371.0672; found 371.0678.

1-((4-(tert-butyl)phenyl)sulfonyl)-2,3-dimethyl-1*H*-benzo[*d*]imidazol-3-i^{um} trifluoromethanesulfonate (1d)


 89%; white solid; 1H NMR (400 MHz, CD_3CN) δ 8.36 – 8.33 (m, 1H), 8.17 – 8.12 (m, 2H), 7.85 – 7.83 (m, 1H), 7.77 – 7.72 (m, 4H), 3.94 (s, 3H), 3.10 (s, 3H), 1.30 (s, 9H). ^{13}C NMR (101 MHz, CD_3CN) δ 162.7, 155.1, 133.0, 132.6, 129.9, 129.6, 129.4, 128.9, 128.6, 116.0, 114.5, 36.4, 33.5, 31.0, 13.8. ^{19}F NMR (377 MHz, CD_3CN) δ -79.28.

IR (neat) ν (cm⁻¹): 3065.7, 2972.6, 1591.6, 1464.8, 1399.6, 1259.8, 1153.6, 1082.8, 1026.9, 959.8, 840.5, 762.2, 622.5, 577.7; HRMS (ESI): calcd for C₁₉H₂₃N₂O₂S⁺ [M]⁺ 343.1475; found 343.1483.

1-((3-chloro-4-fluorophenyl)sulfonyl)-2,3-dimethyl-1*H*-benzo[*d*]imidazol-3-ium trifluoromethanesulfonate (1e)

 87%; white solid; ¹H NMR (400 MHz, CD₃CN) δ 8.37 – 8.31 (m, 2H), 8.25 – 8.20 (m, 1H), 7.88 – 7.85 (m, 1H), 7.81 – 7.72 (m, 2H), 7.57 (t, *J* = 8.8 Hz, 1H), 3.96 (s, 3H), 3.10 (s, 3H). ¹³C NMR (101 MHz, CD₃CN) δ 164.1 (d, *J* = 260.7 Hz), 155.5, 133.0 (d, *J* = 3.6 Hz), 132.6, 132.5 (d, *J* = 1.9 Hz), 131.3 (d, *J* = 10.1 Hz), 129.9, 129.9, 129.1, 124.5 (d, *J* = 19.3 Hz), 122.0 (q, *J* = 320.6 Hz), 120.0 (d, *J* = 23.4 Hz), 116.0, 114.6, 33.7, 13.9. ¹⁹F NMR (377 MHz, CD₃CN) δ -79.30, -102.18 – -102.23. IR (neat) ν (cm⁻¹): 3088.1, 1578.5, 1466.7, 1410.8, 1254.2, 1161.1, 1097.7, 1028.7, 963.5, 894.6, 862.9, 758.5, 635.5, 574.0; HRMS (ESI): calcd for C₁₅H₁₃ClFN₂O₂S⁺ [M]⁺ 339.0365; found 339.0371.

1-((3-chlorophenyl)sulfonyl)-2,3-dimethyl-1*H*-benzo[*d*]imidazol-3-ium trifluoromethanesulfonate (1f)

 85%; white solid; ¹H NMR (400 MHz, CD₃CN) δ 8.35 – 8.32 (m, 1H), 8.21 – 8.15 (m, 2H), 7.89 – 7.84 (m, 2H), 7.80 – 7.68 (m, 4H), 3.95 (s, 3H), 3.10 (s, 3H). ¹³C NMR (101 MHz, CD₃CN) δ 155.4, 138.1, 137.6, 137.0, 133.2, 132.6, 129.9, 129.8, 129.1, 128.9, 128.1, 122.1 (q, *J* = 320.7 Hz), 116.0, 114.6, 33.6, 13.9. ¹⁹F NMR (377 MHz, CD₃CN) δ -79.28. IR (neat) ν (cm⁻¹): 3099.3, 3069.5, 1571.1, 1466.7, 1395.9, 1258.0, 1161.1, 1030.6, 967.2, 889.0, 799.5, 754.8, 669.1, 635.5, 553.5; HRMS (ESI): calcd for C₁₅H₁₄ClN₂O₂S⁺ [M]⁺ 321.0459; found 321.0460.

2,3-dimethyl-1-(naphthalen-2-ylsulfonyl)-1*H*-benzo[*d*]imidazol-3-ium trifluoromethanesulfonate (1g)

93%; white solid; ^1H NMR (400 MHz, CD₃CN) δ 8.96 (d, $J = 1.7$ Hz, 1H), 8.44 (d, $J = 8.4$ Hz, 1H), 8.23 (d, $J = 8.1$ Hz, 1H), 8.15 (d, $J = 8.9$ Hz, 1H), 8.06 – 8.02 (m, 2H), 7.83 – 7.69 (m, 5H), 3.92 (s, 3H), 3.15 (s, 3H). ^{13}C NMR (101 MHz, CD₃CN) δ 155.2, 137.4, 132.9, 132.8, 132.6, 132.5, 132.3, 132.0, 131.0, 130.0, 129.8, 129.7, 129.1, 128.9, 122.5, 122.1 (q, $J = 320.7$ Hz), 116.1, 114.5, 33.5, 13.8. ^{19}F NMR (377 MHz, CD₃CN) δ -79.22. IR (neat) ν (cm⁻¹): 3114.2, 3063.9, 1559.9, 1464.8, 1401.5, 1261.7, 1146.2, 1071.6, 1028.7, 963.5, 894.6, 859.2, 818.2, 758.5, 631.8; HRMS (ESI): calcd for C₁₉H₁₇N₂O₂S⁺ [M]⁺ 337.1005; found 337.1012.

1-((4-cyanophenyl)sulfonyl)-2,3-dimethyl-1H-benzo[d]imidazol-3-ium trifluoromethanesulfonate (1h)


83%; white solid; ^1H NMR (400 MHz, CD₃CN) δ 8.37 – 8.31 (m, 3H), 8.06 – 8.03 (m, 2H), 7.88 – 7.85 (m, 1H), 7.81 – 7.72 (m, 2H), 3.96 (s, 1H), 3.10 (s, 3H). ^{13}C NMR (101 MHz, CD₃CN) δ 155.6, 139.6, 135.3, 132.6, 132.6, 130.2, 129.9, 129.9, 129.2, 122.0 (q, $J = 320.7$ Hz), 120.8, 117.6, 115.9, 114.7, 33.7, 13.9. ^{19}F NMR (377 MHz, CD₃CN) δ -79.23. IR (neat) ν (cm⁻¹): 3103.0, 3045.2, 2238.3, 1559.9, 1466.7, 1397.8, 1258.0, 1159.2, 1026.9, 965.4, 894.6, 846.1, 756.6, 684.0, 626.2, 574.0, 512.5; HRMS (ESI): calcd for C₁₆H₁₄N₃O₂S⁺ [M]⁺ 312.0801; found 312.0808.

1-((2,3-dihydrobenzofuran-5-yl)sulfonyl)-2,3-dimethyl-1H-benzo[d]imidazol-3-ium trifluoromethanesulfonate (1i)


88%; white solid; ^1H NMR (400 MHz, CD₃CN) δ 8.32 – 8.29 (m, 1H), 8.04 – 8.01 (m, 2H), 7.84 – 7.82 (m, 1H), 7.77 – 7.69 (m, 2H), 6.98 – 6.95 (m, 1H), 4.70 (t, $J = 8.9$ Hz, 2H), 3.94 (s, 3H), 3.27 (t, $J = 8.9$ Hz, 2H), 3.08 (s, 3H). ^{13}C NMR (101 MHz, CD₃CN) δ 168.6, 154.8, 132.5, 132.3, 132.3, 130.0, 129.4, 128.7, 127.1, 126.3, 122.1 (q, $J = 320.9$ Hz), 116.1, 114.4, 111.3, 74.7, 33.4, 29.2, 13.7. ^{19}F NMR (377 MHz, CD₃CN) δ -79.3. IR (neat) ν (cm⁻¹): 3103.0, 1600.9, 1466.7, 1384.7, 1248.7, 1151.7,

1030.6, 954.2, 890.8, 829.3, 754.8, 635.5, 583.3, 516.2; HRMS (ESI): calcd for C₁₇H₁₇N₂O₃S⁺ [M]⁺ 329.0954; found 329.0961.


1-(mesitylsulfonyl)-2,3-dimethyl-1*H*-benzo[*d*]imidazol-3-ium trifluoromethanesulfonate (1j)



2,3-dimethyl-1-((2,4,6-triisopropylphenyl)sulfonyl)-1*H*-benzo[*d*]imidazol-3-ium trifluoromethanesulfonate (1k)




1-(benzo[b]thiophen-3-ylsulfonyl)-2,3-dimethyl-1*H*-benzo[*d*]imidazol-3-ium trifluoromethanesulfonate (1l)




(s, 3H). ^{19}F NMR (471 MHz, CD₃CN) δ -79.33. ^{13}C NMR (126 MHz, CD₃CN) δ 155.2, 145.4, 141.3, 133.7, 132.3, 130.4, 129.7, 128.9, 128.2, 128.0, 127.8, 124.9, 122.9, 122.1 (q, J = 321.0 Hz), 116.3, 114.5, 33.5, 13.8. IR (neat) ν (cm⁻¹): 3117.9, 3069.5, 1604.6, 1559.9, 1453.7, 1407.1, 1259.8, 1144.3, 1028.7, 974.7, 751.1; HRMS (ESI): calcd for C₁₇H₁₅N₂O₂S₂⁺ [M]⁺ 343.0569; found 343.0568.

1-((2-(methoxycarbonyl)thiophen-3-yl)sulfonyl)-2,3-dimethyl-1*H*-benzo[*d*]imidazol-3-i um trifluoromethanesulfonate (1m)

 87%; white solid; ^1H NMR (500 MHz, CD₃CN) δ 8.03 – 7.99 (m, 3H), 7.90 – 7.88 (m, 1H), 7.76 – 7.68 (m, 2H), 4.02 (s, 3H), 3.75 (s, 3H), 3.11 (s, 3H). ^{19}F NMR (471 MHz, CD₃CN) δ -79.31. ^{13}C NMR (126 MHz, CD₃CN) δ 159.8, 156.3, 138.9, 137.1, 134.0, 132.8, 132.1, 130.6, 129.3, 128.6, 122.0 (q, J = 320.9 Hz), 116.2, 114.5, 54.2, 33.6, 14.1. IR (neat) ν (cm⁻¹): 3114.2, 3076.9, 1727.6, 1466.7, 1390.3, 1265.4, 1198.3, 1146.2, 1028.7, 965.4, 758.5; HRMS (ESI): calcd for C₁₅H₁₅N₂O₄S₂⁺ [M]⁺ 351.0468; found 351.0467.

1-((2,4-dimethylphenyl)sulfonyl)-2,3-dimethyl-1*H*-benzo[*d*]imidazol-3-i um trifluoromethanesulfonate (1n)

 94%; white solid; ^1H NMR (500 MHz, CD₃CN) δ 8.25 – 8.19 (m, 2H), 7.90 – 7.86 (m, 1H), 7.75 – 7.70 (m, 2H), 7.42 (d, J = 8.2 Hz, 1H), 7.33 (s, 1H), 3.95 (s, 3H), 2.90 (s, 3H), 2.42 – 2.41 (m, 6H). ^{13}C NMR (126 MHz, CD₃CN) δ 154.9, 150.1, 141.0, 135.5, 132.5, 132.3, 131.7, 131.0, 129.4, 129.0, 128.7, 122.0 (q, J = 320.8 Hz), 116.3, 114.5, 33.5, 21.7, 20.7, 13.6. ^{19}F NMR (471 MHz, CD₃CN) δ -79.27. IR (neat) ν (cm⁻¹): 3129.1, 1567.3, 1464.8, 1364.2, 1271.0, 1224.4, 1149.9, 1028.7, 963.5, 894.6, 751.1; HRMS (ESI): calcd for C₁₇H₁₉N₂O₂S⁺ [M]⁺ 315.1162; found 315.1160.

IV. General Procedures

IV-1. General Procedure for the synthesis of the products 3, 5, 7, 10, 12.


Under argon, to a suspension of $\text{Ni}(\text{OTf})_2$ (0.04 mmol, 20 mol%), 4,4'-di-tert-butyl-2,2'-bipyridine (0.04 mmol, 20 mol%), MgCl_2 (0.4 mmol, 2.0 equiv), Zn powder (0.6 mmol, 3.0 equiv), benzimidazolium sulfonamides **1** (0.40 mmol, 2.0 equiv) and PPh_3 (0.5 mmol, 2.5 equiv) in DMA (2 mL) was added corresponding halide (0.2 mmol) at room temperature. After that, the reaction mixture was stirred at 60 °C until the reaction was completed as monitored by TLC or GC-MS analysis. Then, distilled water (40 mL) was added and the aqueous layer was extracted with Et_2O ($3 \times 15\text{mL}$). The combined organic layers were dried over Na_2SO_4 , filtered and concentrated. The product was purified by flash column chromatography on silica gel with *n*-pentane/ethyl acetate as eluent to give the corresponding product **3**, **5**, **7**, **10**, **12**.

IV-2. General Procedure for the synthesis of the products 9a-9i.

Under argon, to a suspension of $\text{Ni}(\text{OTf})_2$ (0.04 mmol, 20 mol%), 4-(trifluoromethyl)pyridine (0.2 mmol, 1.0 equiv), MgCl_2 (0.4 mmol, 2.0 equiv), Zn powder (0.6 mmol, 3.0 equiv), benzimidazolium sulfonamides **1** (0.40 mmol, 2.0 equiv) and PPh_3 (0.5 mmol, 2.5 equiv) in THF (2 mL) was added the corresponding halide (0.2 mmol) at room temperature. After that, the reaction mixture was stirred at 60 °C until the reaction was completed as monitored by TLC or GC-MS analysis. Then, distilled water (30 mL) was added and the aqueous layer was extracted with Et_2O ($3 \times 15\text{ mL}$). The combined organic layers were dried over Na_2SO_4 , filtered and concentrated. The product was purified by flash column chromatography on silica gel with *n*-pentane/ethyl acetate as eluent to give the corresponding product **9a-9i**.


V. Mechanistic Studies


Control Experiment (a):




Under argon, to a solution of benzimidazolium sulfonamide **1a** (0.20 mmol, 2.0 equiv) in CD_3CN (1 mL) was added PPh_3 (0.4 mmol, 2 equiv) at room temperature. Then, the reaction mixture was immediately monitored by ^1H NMR and ^{31}P NMR for 2 h. The

intermediate **Int-I** and O=PPh₃ were detected by ¹H NMR and ³¹P NMR, respectively. Meanwhile, the intermediate **Int-I** was detected by HRMS.






Control Experiment (b):



Under argon, to a solution of benzimidazolium sulfonamide **1a** (0.20 mmol, 2.0 equiv) in CH₃CN (1 mL) was added PPh₃ (0.4 mmol, 2 equiv) at room temperature. After 3 hours, Ni(OTf)₂ (0.02 mmol, 20 mol%), 4,4'-di-*tert*-butyl-2,2'-bipyridine (0.02 mmol, 20 mol%), MgCl₂ (0.2 mmol, 2.0 equiv), Zn powder (0.3 mmol, 3.0 equiv), 1-iodo-4-methoxybenzene **2a** (0.10 mmol) and DMA (1 mL) were added to the reaction mixture. After that, the reaction mixture was stirred at 60 °C for 8 h. Then, distilled water (40 mL) was added and the aqueous layer was extracted with Et₂O (3 × 15mL). The combined organic layers were dried over Na₂SO₄, filtered and concentrated. The product was purified by flash column chromatography on silica gel with *n*-pentane/ethyl acetate as eluent to give the corresponding product **3a** in 80% yield.


Control Experiment (c):

The synthesis of nickel-complex **14**




A solution of (dtbbpy)Ni(cod) was generated by stirring 138 mg of Ni(cod)₂ (0.5 mmol) and 134 mg of 4,4'-di-*tert*-butyl-2,2'-bipyridine (0.5 mmol) in 5 mL of THF overnight at room temperature in an argon-filled glovebox. Upon dissolution of the solids, the reaction mixture became dark purple. To this purple mixture was added 0.076 mL of 2-iodotoluene **2a** (131 mg, 0.6 mmol) and the color rapidly changed to red, indicating

formation of **14**. The solution was stirred for an additional 2 h before the solvent was removed under vacuum. The solid was triturated with dry, degassed pentane three times to remove residual cyclooctadiene and 2-iodotoluene and then dried under vacuum overnight to provide 236 mg of **14** (87% yield). ¹H NMR (400 MHz, Acetone) δ 9.56 (d, *J* = 5.5 Hz, 1H), 8.40 (d, *J* = 12.7 Hz, 2H), 7.66 – 7.55 (m, 2H), 7.38 (d, *J* = 4.9 Hz, 1H), 6.85 – 6.60 (m, 4H), 2.95 (s, 3H), 1.42 (s, 9H), 1.37 (s, 9H). ¹³C NMR (101 MHz, Acetone) δ 164.5, 164.1, 156.7, 154.2, 154.1, 149.9, 149.0, 143.5, 138.5, 127.8, 124.4, 124.3, 123.6, 122.6, 119.7, 119.3, 36.2 (2C), 30.4, 27.2.



Under argon, to a solution of benzimidazolium sulfonamide **1a** (0.20 mmol, 2.0 equiv) in CH_3CN (1 mL) was added PPh_3 (0.4 mmol, 2 equiv) at room temperature. After 3 hours, the nickel-complex **14** (0.1 mmol, 54.4 mg), MgCl_2 (0.2 mmol, 2.0 equiv) and DMA (1 mL) were added to the reaction mixture. After that, the reaction mixture was stirred at 60°C for 8 h. Then, distilled water (40 mL) was added and the aqueous layer was extracted with Et_2O ($3 \times 15\text{mL}$). The combined organic layers were dried over Na_2SO_4 , filtered and concentrated. The product was purified by flash column chromatography on silica gel with *n*-pentane/ethyl acetate as eluent to give the corresponding product **3d** in 15% yield.

Control Experiment (d):



Under argon, to a suspension of $\text{Ni}(\text{OTf})_2$ (0.04 mmol, 20 mol%), 4,4'-di-*tert*-butyl-2,2'-bipyridine (0.04 mmol, 20 mol%), MgCl_2 (0.4 mmol, 2.0 equiv), Zn powder (0.6 mmol, 3.0 equiv) and PPh_3 (0.5 mmol, 2.5 equiv) in DMA (2 mL) was added 1-methoxy-4-tosylbenzene **15** (0.2 mmol) at room temperature. After that, the reaction mixture was stirred at 60°C for 8 h. Then, distilled water (40 mL) was added and the aqueous layer was extracted with Et_2O ($3 \times 15\text{mL}$). The combined organic layers were

dried over Na_2SO_4 , filtered and concentrated. Experimental results show that the desired product **3a** was not formed and substrate **15** was recovered in 94% yield.

VI. Characteristic Data

(4-methoxyphenyl)(*p*-tolyl)sulfane (**3a**)

92% (42.4 mg, X = I); Gram-scale: 60% (685 mg, X = I);
 81% (37.2 mg, X = Br); white solid; mp 41-42 °C; ^1H NMR (400 MHz, CDCl_3) δ 7.38 – 7.34 (m, 2H), 7.14 – 7.11 (m, 2H), 7.07 – 7.04 (m, 2H), 6.88 – 6.84 (m, 2H), 3.80 (s, 3H), 2.30 (s, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ 159.4, 136.1, 134.3, 129.7, 129.3, 128.5, 125.6, 114.8, 55.3, 21.0. IR (neat) ν (cm $^{-1}$): 3067.6, 3002.4, 2920.4, 2834.6, 1589.7, 1489.1, 1241.2, 1172.2, 1030.6, 801.4; HRMS (ESI): calcd for $\text{C}_{14}\text{H}_{15}\text{OS}^+$ [M + H] $^+$ 231.0838; found 231.0833.


p-tolyl(4-(trifluoromethoxy)phenyl)sulfane (**3b**)

72% (20.4 mg); white solid; mp 37-38 °C; ^1H NMR (400 MHz, CDCl_3) δ 7.33 – 7.31 (m, 2H), 7.23 (m, J = 5.1, 3.8 Hz, 2H), 7.18 – 7.15 (m, 2H), 7.11 – 7.08 (m, 2H), 2.36 (s, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ 147.6, 138.3, 136.4, 132.8, 130.3, 130.3, 121.6, 120.4 (q, J = 257.3 Hz), 21.2. IR (neat) ν (cm $^{-1}$): 3022.9, 2929.7, 2873.8, 1595.3, 1487.2, 1217.0, 1157.3, 1080.9, 1015.7, 803.2; HRMS (ESI): calcd for $\text{C}_{14}\text{H}_{12}\text{F}_3\text{OS}^+$ [M + H] $^+$ 285.0555; found 285.0568.

(2,4-dimethoxyphenyl)(*p*-tolyl)sulfane (**3c**)


82% (42.6 mg); white solid; mp 64-65 °C; ^1H NMR (500 MHz, CDCl_3) δ 7.25 – 7.23 (m, 1H), 7.11 – 7.08 (m, 2H), 7.05 – 7.04 (m, 2H), 6.50 (d, J = 2.5 Hz, 1H), 6.47 – 6.45 (m, 1H), 3.81 (s, 3H), 3.81 (s, 3H), 2.29 (s, 3H). ^{13}C NMR (126 MHz, CDCl_3) δ 161.3, 159.7, 135.7, 135.4, 133.3, 129.6, 128.9, 113.5, 105.2, 99.1, 55.9, 55.4, 21.0. IR (neat) ν (cm $^{-1}$): 3071.3, 3002.4, 2937.1, 2834.6, 1591.6, 1459.3, 1299.0, 1207.7, 1161.1, 1073.5, 1028.7, 803.2; HRMS (ESI): calcd for $\text{C}_{15}\text{H}_{16}\text{O}_2\text{SNa}^+$ [M + Na] $^+$ 283.0763; found 283.0761.

***o*-tolyl(*p*-tolyl)sulfane (**3d**)**




89% (38.1 mg); colorless liquid; ^1H NMR (400 MHz, CDCl_3) δ 7.24 – 7.07 (m, 8H), 2.37 (s, 3H), 2.32 (s, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ 138.7, 136.9, 135.2, 131.6, 131.3, 131.0, 130.4, 130.0, 127.1, 126.6, 21.1, 20.5. IR (neat) ν (cm^{-1}): 3058.3, 3013.6, 2920.4, 2860.7, 1589.7, 1490.9, 1466.7, 1060.4, 1015.7, 803.2, 743.6; HRMS (ESI): calcd for $\text{C}_{14}\text{H}_{15}\text{S}^+$ [M + H] $^+$ 215.0889; found 215.0888.

1-(4-(*p*-tolylthio)phenyl)ethan-1-one (3e**)**




63% (30.5 mg); white solid; mp 89–90 °C; ^1H NMR (400 MHz, CDCl_3) δ 7.81 – 7.77 (m, 2H), 7.42 – 7.39 (m, 2H), 7.24 (t, $J = 9.2$ Hz, 2H), 7.17 – 7.13 (m, 2H), 2.54 (s, 3H), 2.39 (s, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ 197.1, 145.9, 139.3, 134.5, 134.1, 130.5, 128.8, 127.9, 126.6, 26.4, 21.3. IR (neat) ν (cm^{-1}): 3324.8, 3080.6, 2922.2, 2851.4, 1671.7, 1578.5, 1395.9, 1261.7, 1088.4, 959.8, 814.4; HRMS (ESI): calcd for $\text{C}_{15}\text{H}_{15}\text{OS}^+$ [M + H] $^+$ 243.0838; found 243.0839.

methyl 4-(*p*-tolylthio)benzoate (3f**)**



84% (43.3 mg); white solid; mp 73–74 °C; ^1H NMR (400 MHz, CDCl_3) δ 7.88 – 7.85 (m, 2H), 7.42 – 7.39 (m, 2H), 7.23 – 7.20 (m, 2H), 7.16 – 7.12 (m, 2H), 3.88 (s, 3H), 2.39 (s, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ 166.8, 145.4, 139.2, 134.4, 130.5, 130.0, 128.1, 127.0, 126.7, 52.0, 21.3. IR (neat) ν (cm^{-1}): 3017.3, 2946.5, 2922.2, 2849.5, 1705.3, 1589.7, 1431.3, 1272.9, 1183.4, 1112.6, 814.4, 762.2; HRMS (ESI): calcd for $\text{C}_{15}\text{H}_{15}\text{O}_2\text{S}^+$ [M + H] $^+$ 259.0787; found 259.0785.


4,4,5,5-tetramethyl-2-(4-(*p*-tolylthio)phenyl)-1,3,2-dioxaborolane (3g**)**




89% (58.2 mg); white solid; mp 122–123 °C; ^1H NMR (400 MHz, CDCl_3) δ 7.67 (d, $J = 8.1$ Hz, 2H), 7.34 – 7.31 (m, 2H), 7.21 – 7.18 (m, 2H), 7.16 – 7.13 (m, 2H), 2.35 (s, 3H), 1.32 (s, 12H). ^{13}C NMR (101 MHz, CDCl_3) δ 141.6, 138.1, 135.2, 133.0, 130.1, 130.1, 127.8, 83.8, 24.8, 21.2.

IR (neat) ν (cm⁻¹): 3000.5, 2980.0, 2924.1, 1593.4, 1354.9, 1142.4, 1015.7, 857.3, 812.6, 650.4; HRMS (ESI): calcd for C₁₉H₂₄BO₂S⁺ [M + H]⁺ 327.1585; found 327.1587.


[1,1'-biphenyl]-4-yl(*p*-tolyl)sulfane (3h)

 94% (52.2 mg); colorless liquid; ¹H NMR (400 MHz, CDCl₃) δ 7.56 – 7.53 (m, 2H), 7.50 – 7.47 (m, 2H), 7.43 – 7.39 (m, 2H), 7.35 – 7.30 (m, 5H), 7.16 – 7.14 (m, 2H), 2.34 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 140.4, 139.3, 137.7, 136.3, 132.4, 131.1, 130.1, 130.0, 128.8, 127.7, 127.3, 126.9, 21.1. IR (neat) ν (cm⁻¹): 3028.5, 2918.5, 2853.3, 1904.7, 1654.9, 1591.6, 1474.2, 1395.9, 1207.7, 1084.7, 810.7, 752.9, 687.7; HRMS (ESI): calcd for C₁₉H₁₇S⁺ [M + H]⁺ 277.1045; found 277.1035.


5-(*p*-tolylthio)benzo[*d*][1,3]dioxole (3i)

 91% (44.4 mg); colorless liquid; ¹H NMR (400 MHz, CDCl₃) δ 7.20 – 7.16 (m, 2H), 7.08 (d, *J* = 8.0 Hz, 2H), 6.93 (dd, *J* = 8.0, 1.8 Hz, 2H), 6.84 (d, *J* = 1.8 Hz, 1H), 6.76 (d, *J* = 8.0 Hz, 1H), 5.95 (s, 2H), 2.31 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 148.2, 147.5, 136.6, 133.5, 130.1, 129.8, 127.7, 126.1, 112.6, 108.8, 101.3, 21.0. IR (neat) ν (cm⁻¹): 3069.5, 3013.6, 2888.7, 2775.0, 1474.2, 1230.0, 1036.2, 933.7, 889.0, 801.4, 603.8; HRMS (ESI): calcd for C₁₄H₁₃O₂S⁺ [M + H]⁺ 245.0631; found 245.0629.


(9*H*-fluoren-2-yl)(*p*-tolyl)sulfane (3j)

 82% (47.4 mg); white solid; mp 108–109 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.74 (d, *J* = 7.5 Hz, 1H), 7.68 (d, *J* = 8.0 Hz, 1H), 7.52 – 7.48 (m, 2H), 7.38 – 7.33 (m, 2H), 7.31 – 7.27 (m, 3H), 7.14 – 7.11 (m, 2H), 3.84 (s, 2H), 2.34 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 144.2, 143.1, 141.0, 140.7, 137.2, 134.6, 132.4, 131.4, 130.0, 129.4, 127.3, 126.8, 126.8, 125.0, 120.3, 119.9, 36.8, 21.1. IR (neat) ν (cm⁻¹): 3047.1, 2924.1, 2853.3, 1654.9, 1559.9, 1444.3, 954.2, 810.7, 732.4, 631.8, 572.1; HRMS (EI): calcd for C₂₀H₁₆S [M] 288.0973; found 288.0974.


4-(*p*-tolylthio)aniline (3k**)**


Me 57% (24.7 mg); white solid; mp 66-67 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.29 – 7.25 (m, 2H), 7.09 – 7.01 (m, 4H), 6.66 – 6.63 (m, 2H), 3.76 (s, 2H), 2.28 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 146.6, 135.5, 135.4, 135.3, 129.6, 128.2, 121.7, 115.8, 20.9. IR (neat) ν (cm⁻¹): 3464.6, 3358.3, 3199.9, 3030.3, 2914.8, 1597.2, 1489.1, 1299.0, 1176.0, 1082.8, 1015.7, 797.7; HRMS (ESI): calcd for C₁₃H₁₄NS⁺ [M + H]⁺ 216.0841; found 216.0839.


2-(*p*-tolylthio)phenol (3l**)**


Me 60% (26.3 mg); colorless liquid; ¹H NMR (400 MHz, CDCl₃) δ 7.51 (dd, *J* = 7.7, 1.6 Hz, 1H), 7.37 – 7.32 (m, 1H), 7.06 – 7.00 (m, 4H), 6.95 – 6.91 (m, 1H), 6.53 (s, 1H), 2.28 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 157.1, 136.6, 136.3, 132.1, 132.0, 130.0, 127.4, 121.2, 117.2, 115.4, 20.9. IR (neat) ν (cm⁻¹): 3419.8, 3021.0, 2920.4, 2862.6, 1572.9, 1468.6, 1338.1, 1289.7, 1181.6, 1026.9, 803.2, 751.1; HRMS (ESI): calcd for C₁₃H₁₂OS⁺ [M + Na]⁺ 239.0501; found 239.0500.

***p*-tolyl(4-vinylphenyl)sulfane (**3m**)**



Me 49% (22.2 mg); colorless liquid; ¹H NMR (400 MHz, CDCl₃) δ 7.32 – 7.28 (m, 4H), 7.23 – 7.19 (m, 2H), 7.15 – 7.12 (m, 2H), 6.66 (dd, *J* = 17.6, 10.9 Hz, 1H), 5.71 (dd, *J* = 17.6, 0.7 Hz, 1H), 5.23 (dd, *J* = 10.9, 0.7 Hz, 1H), 2.34 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 137.6, 136.6, 136.1, 135.9, 132.2, 130.1, 129.9, 129.9, 126.8, 113.9, 21.1. IR (neat) ν (cm⁻¹): 3069.5, 3022.9, 2965.1, 2920.4, 2860.7, 1489.1, 1395.9, 1082.8, 987.7, 905.7, 807.0; HRMS (ESI): calcd for C₁₅H₁₅S⁺ [M + H]⁺ 227.0889; found 227.0887.

3-(*p*-tolylthio)thiophene (3n**)**



Me 74% (30.7 mg); white solid; mp 30-31 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.34 (dd, *J* = 5.0, 3.0 Hz, 1H), 7.28 (dd, *J* = 3.0, 1.3 Hz, 1H), 7.19 – 7.15 (m, 2H), 7.10 – 7.07 (m, 2H), 7.00 (dd, *J* = 5.0, 1.3 Hz, 1H), 2.31 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 136.5, 133.1, 130.7, 130.6, 129.8, 129.5, 126.6,

126.5, 21.0. IR (neat) ν (cm⁻¹): 3393.7, 3103.0, 3019.1, 2918.5, 2849.5, 1489.1, 1351.2, 1198.3, 1086.5, 1015.7, 851.7, 803.2, 775.3, 613.1; HRMS (ESI): calcd for C₁₁H₁₁S₂⁺ [M + H]⁺ 207.0297; found 207.0292.


1-methyl-4-(*p*-tolylthio)-1*H*-pyrazole (3o)

 56% (22.6 mg); colorless liquid; ¹H NMR (400 MHz, CDCl₃) δ 7.56 (s, 1H), 7.49 (s, 1H), 7.06 – 7.01 (m, 4H), 3.91 (s, 3H), 2.27 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 144.4, 135.3, 135.1, 134.9, 129.5, 126.8, 108.3, 39.3, 20.8. IR (neat) ν (cm⁻¹): 3117.9, 3017.3, 2920.4, 2866.3, 1490.9, 1438.8, 1116.3, 974.7, 803.2, 704.5, 657.9, 622.5; HRMS (ESI): calcd for C₁₁H₁₃N₂S⁺ [M + H]⁺ 205.0794; found 205.0793.


6-(*p*-tolylthio)quinolone (3p)

 38% (19.3 mg); colorless liquid; ¹H NMR (400 MHz, CDCl₃) δ 8.84 (dd, *J* = 4.2, 1.7 Hz, 1H), 8.01 – 7.96 (m, 2H), 7.61 – 7.52 (m, 2H), 7.41 – 7.34 (m, 3H), 7.21 – 7.18 (m, 2H), 2.38 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 150.0, 146.9, 138.4, 136.5, 135.2, 133.1, 130.6, 130.3, 130.0, 130.0, 128.6, 126.5, 121.6, 21.2. IR (neat) ν (cm⁻¹): 3021.0, 2920.4, 2858.9, 1586.0, 1485.3, 1179.7, 1121.9, 943.0, 864.7, 807.0, 766.0, 605.7; HRMS (ESI): calcd for C₁₆H₁₄NS⁺ [M + H]⁺ 252.0841; found 252.0843.


3-(*p*-tolylthio)-9*H*-carbazole (3q)

 70% (40.0 mg); white solid; mp 194–195 °C; ¹H NMR (400 MHz, DMSO) δ 11.49 (s, 1H), 8.33 (d, *J* = 1.7 Hz, 1H), 8.16 (d, *J* = 7.8 Hz, 1H), 7.56 – 7.40 (m, 4H), 7.20 – 7.15 (m, 1H), 7.11 – 7.05 (m, 4H), 2.23 (s, 3H). ¹³C NMR (101 MHz, DMSO) δ 140.2, 139.7, 135.4, 135.3, 131.5, 129.8, 127.9, 126.4, 126.2, 123.6, 121.9, 121.3, 120.6, 119.1, 112.3, 111.2, 20.5. IR (neat) ν (cm⁻¹): 3397.5, 2916.6, 2849.5, 1891.6, 1597.2, 1449.9, 1332.5, 1239.3, 1088.4, 1015.7, 939.3, 883.4, 803.2, 726.8; HRMS (ESI): calcd for C₁₉H₁₆NS⁺ [M + H]⁺ 290.0998; found 290.0994.


5-(*p*-tolylthio)-1*H*-indole (3r)

 **Me** 85% (40.7 mg); white solid; mp 51-53 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.19 (s, 1H), 7.80 – 7.79 (m, 1H), 7.35 – 7.32 (m, 1H), 7.28 (dd, *J* = 8.5, 1.6 Hz, 1H), 7.21 – 7.19 (m, 1H), 7.13 – 7.11 (m, 2H), 7.04 – 7.01 (m, 1H), 6.52 – 6.50 (m, 1H), 2.28 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 135.5, 135.5, 135.4, 129.6, 128.8, 128.7, 127.5, 126.4, 125.0, 124.2, 112.0, 102.7, 20.9. IR (neat) ν (cm⁻¹): 3412.4, 3017.3, 2918.5, 2860.7, 1489.1, 1451.8, 1410.8, 1308.3, 1084.7, 1015.7, 799.5, 762.2, 723.1, 598.2; HRMS (ESI): calcd for C₁₅H₁₄NS⁺ [M + H]⁺ 240.0841; found 240.0840.


4-(*p*-tolylthio)isothiazole (**3s**)

 **Me** 58% (24.1 mg); colorless liquid; ¹H NMR (400 MHz, CDCl₃) δ 8.49 (s, 1H), 8.36 (s, 1H), 7.22 – 7.19 (m, 2H), 7.12 – 7.10 (m, 2H), 2.32 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 159.6, 147.9, 137.5, 131.5, 130.3, 130.1, 129.6, 21.0. IR (neat) ν (cm⁻¹): 3049.0, 2916.6, 2860.7, 1490.9, 1347.4, 1300.8, 1207.7, 1086.5, 1015.7, 920.7, 801.4, 616.9; HRMS (ESI): calcd for C₁₀H₁₀NS₂⁺ [M + H]⁺ 208.0249; found 208.0247.

3-(*p*-tolylthio)benzofuran (**3t**)


 The product **3t** was prepared at 80 °C in 77% yield (37.3 mg); white solid; mp 46-47 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.82 (s, 1H), 7.53 – 7.45 (m, 2H), 7.34 – 7.30 (m, 1H), 7.24 – 7.19 (m, 1H), 7.15 – 7.12 (m, 2H), 7.04 – 7.01 (m, 2H), 2.27 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 155.7, 148.2, 135.9, 132.2, 129.7, 128.1, 127.9, 125.0, 123.3, 120.3, 111.8, 111.2, 20.9. IR (neat) ν (cm⁻¹): 3131.0, 3021.0, 2920.4, 2862.6, 1490.9, 1448.1, 1250.5, 1161.1, 1090.2, 1015.7, 803.2, 747.3; HRMS (ESI): calcd for C₁₅H₁₃OS⁺ [M + H]⁺ 241.0682; found 241.0670.

3-(*p*-tolylthio)benzo[b]thiophene (**3u**)


 The product **3u** was prepared at 80 °C in 83% yield (42.7 mg); colorless liquid; ¹H NMR (400 MHz, CDCl₃) δ 7.88 – 7.77 (m, 2H), 7.60 (s, 1H), 7.39 – 7.32 (m, 2H), 7.12 – 7.09 (m, 2H), 7.03

– 7.00 (m, 2H), 2.26 (s, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ 140.0, 138.8, 136.1, 132.5, 130.8, 129.8, 128.4, 125.0, 124.9, 124.7, 123.0, 122.8, 20.9. IR (neat) ν (cm^{-1}): 3095.6, 3054.6, 3019.1, 2918.5, 2860.7, 1489.1, 1420.1, 1310.2, 1252.4, 1086.5, 1015.7, 803.2, 754.8, 702.6; HRMS (ESI): calcd for $\text{C}_{15}\text{H}_{13}\text{S}_2^+$ [M + H] $^+$ 257.0453; found 257.0443.


2-methyl-5-(*p*-tolylthio)benzo[*d*]thiazole (3v)

 56% (30.2 mg); white solid; mp 70–71 °C; ^1H NMR (500 MHz, CDCl_3) δ 7.77 (d, $J = 1.7$ Hz, 1H), 7.69 (d, $J = 8.4$ Hz, 1H), 7.35 – 7.32 (m, 2H), 7.28 (dd, $J = 8.4, 1.8$ Hz, 2H), 7.15 – 7.13 (m, 2H), 2.80 (s, 3H), 2.34 (s, 3H). ^{13}C NMR (126 MHz, CDCl_3) δ 167.9, 154.0, 137.9, 135.5, 133.7, 132.6, 130.8, 130.2, 126.3, 123.2, 121.6, 21.1, 20.1. IR (neat) ν (cm^{-1}): 3049.0, 2916.6, 2587.0, 1891.6, 1522.6, 1489.1, 1407.1, 1295.2, 1168.5, 1058.6, 1017.6, 903.9, 797.7, 635.5; HRMS (ESI): calcd for $\text{C}_{15}\text{H}_{14}\text{NS}_2^+$ [M + H] $^+$ 272.0562; found 272.0564.

2-(*p*-tolylthio)pyrimidine (3w)


 39% (X = Br, 15.8 mg); 25% (X = Cl, 10.0 mg); white solid; mp 49–50 °C; ^1H NMR (400 MHz, CDCl_3) δ 8.48 (d, $J = 4.8$ Hz, 2H), 7.53 – 7.50 (m, 2H), 7.26 – 7.24 (m, 2H), 6.94 (t, $J = 4.8$ Hz, 1H), 2.40 (s, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ 173.2, 157.5, 139.6, 135.3, 130.1, 125.8, 116.8, 21.4. IR (neat) ν (cm^{-1}): 3356.5, 2918.5, 2851.4, 1545.0, 1490.9, 1369.8, 1170.4, 1103.3, 1015.7, 807.0, 769.7, 516.2; HRMS (ESI): calcd for $\text{C}_{11}\text{H}_{11}\text{N}_2\text{S}^+$ [M + H] $^+$ 203.0637; found 203.0639.

2-methoxy-5-(*p*-tolylthio)pyrazine (3x)


 94% (43.8 mg); colorless liquid; ^1H NMR (400 MHz, CDCl_3) δ 8.11 (d, $J = 1.4$ Hz, 1H), 7.92 (d, $J = 1.4$ Hz, 1H), 7.41 – 7.38 (m, 2H), 7.18 – 7.15 (m, 2H), 3.92 (s, 3H), 2.35 (s, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ 158.8, 146.6, 140.7, 138.6, 135.1, 133.2, 130.3, 128.8, 53.8, 21.2. IR (neat) ν (cm^{-1}): 3019.1, 2980.0, 2942.7, 2857.0, 1565.5, 1528.2, 1455.5, 1420.1,

1328.8, 1267.3, 1161.1, 1019.4, 890.8, 807.0, 676.5; HRMS (ESI): calcd for C₁₂H₁₃N₂OS⁺ [M + H]⁺ 233.0743; found 233.0745.


2-(*p*-tolylthio)pyridine (3y)

 88% (35.4 mg); white solid; mp 31–32 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.41 – 8.39 (m, 1H), 7.50 – 7.47 (m, 2H), 7.44 – 7.39 (m, 1H), 7.25 – 7.22 (m, 2H), 6.98 – 6.94 (m, 1H), 6.85 – 6.82 (m, 1H), 2.39 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 162.1, 149.4, 139.4, 136.5, 135.2, 130.4, 127.2, 120.8, 119.5, 21.3. IR (neat) ν (cm^{−1}): 3043.4, 2920.4, 2864.5, 1571.1, 1492.8, 1446.2, 1414.5, 1278.5, 1123.8, 1043.7, 1017.6, 985.9, 808.8, 754.8, 721.2, 616.9; HRMS (ESI): calcd for C₁₂H₁₂NS⁺ [M + H]⁺ 202.0685; found 202.0687.

3-fluoro-2-(*p*-tolylthio)pyridine (3z)

 74% (32.7 mg); colorless liquid; ¹H NMR (400 MHz, CDCl₃) δ 8.18 (dt, *J* = 4.7, 1.4 Hz, 1H), 7.47 – 7.43 (m, 2H), 7.30 – 7.20 (m, 3H), 7.06 – 7.01 (m, 1H), 2.37 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 156.1 (d, *J* = 257.2 Hz), 145.3 (d, *J* = 5.2 Hz), 139.0, 134.9, 130.0, 125.4, 121.9, 121.7, 121.2 (d, *J* = 2.9 Hz), 21.3. IR (neat) ν (cm^{−1}): 3356.5, 3177.6, 3058.3, 2920.4, 2849.5, 1586.0, 1492.8, 1446.2, 1410.8, 1259.8, 1205.8, 1077.2, 1017.6, 792.1, 725.0, 674.6; HRMS (ESI): calcd for C₁₂H₁₁FNS⁺ [M + H]⁺ 220.0591; found 220.0590.

4-methyl-2-(*p*-tolylthio)pyrimidine (3aa)

 42% (18.4 mg); white solid; mp 40–42 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.30 (d, *J* = 5.1 Hz, 1H), 7.52 – 7.50 (m, 2H), 7.24 – 7.22 (m, 2H), 6.80 (d, *J* = 5.1 Hz, 1H), 2.43 (s, 3H), 2.39 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 172.5, 167.7, 157.1, 139.3, 135.2, 130.0, 126.1, 116.6, 24.1, 21.4. IR (neat) ν (cm^{−1}): 3356.5, 3073.2, 3017.3, 2955.8, 2920.4, 2851.4, 1535.7, 1412.7, 1321.3, 1202.1, 1015.7, 807.0, 702.6, 581.5; HRMS (ESI): calcd for C₁₂H₁₃N₂S⁺ [M + H]⁺ 217.0794; found 217.0792.

5-ethyl-2-(*p*-tolylthio)pyrimidine (3bb)

26% (12.1 mg); colorless liquid; ^1H NMR (400 MHz, CDCl_3) δ 8.34 (s, 2H), 7.52 – 7.50 (m, 2H), 7.25 – 7.23 (m, 2H), 2.54 (q, $J = 7.6$ Hz, 2H), 2.39 (s, 3H), 1.22 (t, $J = 7.6$ Hz, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ 170.2, 157.1, 139.4, 135.2, 132.0, 130.1, 126.2, 23.0, 21.4, 15.0. IR (neat) ν (cm^{-1}): 3017.3, 2967.0, 2924.1, 2871.9, 1578.5, 1537.5, 1492.8, 1388.4, 1233.7, 1155.5, 1017.6, 930.0, 807.0, 629.9; HRMS (ESI): calcd for $\text{C}_{13}\text{H}_{15}\text{N}_2\text{S}^+$ [M + H] $^+$ 231.0950; found 231.0953.

5-fluoro-2-(*p*-tolylthio)pyrimidine (3cc)

34% (14.9 mg); white solid; mp 38-39 °C; ^1H NMR (400 MHz, CDCl_3) δ 8.38 (s, 2H), 7.51 – 7.48 (m, 2H), 7.26 – 7.24 (m, 2H), 2.40 (s, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ 155.6 (d, $J = 261.1$ Hz), 145.6, 145.4, 139.8, 135.3, 130.2, 125.9, 21.4. IR (neat) ν (cm^{-1}): 3035.9, 2922.2, 2862.6, 1554.3, 1492.8, 1384.7, 1239.3, 1174.1, 1017.6, 922.5, 807.0, 760.4, 648.6; HRMS (ESI): calcd for $\text{C}_{11}\text{H}_{10}\text{FN}_2\text{S}^+$ [M + H] $^+$ 221.0543; found 221.0542.

5-((4-(trifluoromethoxy)phenyl)thio)-1*H*-indole (3dd)


89% (55.3 mg); white solid; mp 54-56 °C; ^1H NMR (400 MHz, CDCl_3) δ 8.30 (s, 1H), 7.86 – 7.86 (m, 1H), 7.39 (d, $J = 8.4$ Hz, 1H), 7.33 – 7.30 (m, 1H), 7.25 – 7.23 (m, 1H), 7.15 – 7.10 (m, 2H), 7.03 (dd, $J = 8.9, 0.8$ Hz, 2H), 6.56 – 6.55 (m, 1H). ^{13}C NMR (101 MHz, CDCl_3) δ 146.9, 138.8, 135.8, 129.0, 128.4, 128.3, 127.7, 125.3, 122.2, 121.5, 120.4 (q, $J = 257.0$ Hz), 112.3, 102.9. ^{19}F NMR (377 MHz, CDCl_3) δ -58.0. IR (neat) ν (cm^{-1}): 3397.5, 1485.3, 1455.5, 1217.0, 1155.5, 1084.7, 1013.8, 887.1, 803.2, 728.7, 663.5, 607.6; HRMS (ESI): calcd for $\text{C}_{15}\text{H}_{11}\text{F}_3\text{NOS}^+$ [M + H] $^+$ 310.0508; found 310.0509.

5-((4-(*tert*-butyl)phenyl)thio)-1*H*-indole (3ee)


87% (48.9 mg); white solid; mp 95-96 °C; ^1H NMR (400 MHz, CDCl_3) δ 8.18 (s, 1H), 7.83 – 7.82 (m, 1H), 7.35 – 7.29 (m, 2H), 7.25 – 7.18 (m, 3H), 7.14 – 7.11 (m, 2H), 6.52 – 6.51 (m, 1H), 1.26 (s, 9H). ^{13}C NMR (101 MHz, CDCl_3) δ 148.6, 135.8, 135.5, 128.8, 127.9, 127.9, 126.9,

125.9, 125.0, 123.6, 112.0, 102.7, 34.3, 31.3. IR (neat) ν (cm⁻¹): 3330.4, 2957.6, 2866.3, 1449.9, 1306.4, 1116.3, 1064.2, 885.2, 805.1, 719.4, 603.8; HRMS (ESI): calcd for C₁₈H₂₀NS⁺ [M + H]⁺ 282.1311; found 282.1312.


5-((3-chloro-4-fluorophenyl)thio)-1*H*-indole (3ff)

 83% (46.2 mg); white solid; mp 76-78 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.28 (s, 1H), 7.83 – 7.83 (m, 1H), 7.41 – 7.38 (m, 1H), 7.30 – 7.27 (m, 1H), 7.27 – 7.25 (m, 1H), 7.17 (dd, *J* = 6.8, 2.2 Hz, 1H), 7.04 – 7.00 (m, 1H), 6.99 – 6.94 (m, 1H), 6.57 – 6.55 (m, 1H). ¹³C NMR (101 MHz, CDCl₃) δ 156.3 (d, *J* = 247.4 Hz), 136.3 (d, *J* = 3.8 Hz), 135.8, 129.6, 128.9, 128.0, 127.5 (d, *J* = 6.9 Hz), 127.4, 125.3, 122.5, 121.4 (d, *J* = 18.3 Hz), 116.8 (d, *J* = 21.6 Hz), 112.3, 102.9. IR (neat) ν (cm⁻¹): 3408.7, 2920.4, 2849.5, 1720.2, 1571.1, 1477.9, 1410.8, 1313.9, 1231.9, 1097.7, 1053.0, 885.2, 810.7, 760.4, 730.6, 600.1; HRMS (ESI): calcd for C₁₄H₁₀ClFNS⁺ [M + H]⁺ 278.0201; found 278.0200.

5-((3-chlorophenyl)thio)-1*H*-indole (3gg)


 88% (45.9 mg); white solid; mp 57-58 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.25 (s, 1H), 7.87 – 7.86 (m, 1H), 7.40 – 7.37 (m, 1H), 7.31 (dd, *J* = 8.4, 1.7 Hz, 1H), 7.24 – 7.22 (m, 1H), 7.11 – 6.97 (m, 4H), 6.56 – 6.55 (m, 1H). ¹³C NMR (101 MHz, CDCl₃) δ 142.3, 135.9, 134.7, 129.7, 128.9, 128.5, 128.0, 126.6, 125.3, 125.2, 125.1, 121.5, 112.3, 102.9. IR (neat) ν (cm⁻¹): 3421.7, 3054.6, 2920.4, 2853.2, 1574.8, 1453.7, 1407.1, 1308.3, 1080.9, 889.0, 762.2, 725.0, 676.5, 598.2; HRMS (ESI): calcd for C₁₄H₁₁ClNS⁺ [M + H]⁺ 260.0295; found 260.0293.

5-(naphthalen-2-ylthio)-1*H*-indole (3hh)

 92% (50.8 mg); white solid; mp 130-131 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.20 (s, 1H), 7.89 – 7.88 (m, 1H), 7.75 – 7.72 (m, 1H), 7.67 (d, *J* = 8.7 Hz, 1H), 7.63 – 7.58 (m, 2H), 7.40 – 7.35 (m, 4H), 7.30 (dd, *J* = 8.6, 1.9 Hz, 1H), 7.23 – 7.21 (m, 1H). ¹³C NMR (101 MHz, CDCl₃) δ 137.0, 135.6, 133.8, 131.5, 128.9, 128.3, 128.1, 127.6, 127.1, 127.1, 126.5, 126.4, 125.7,


125.4, 125.1, 123.1, 112.1, 102.8. IR (neat) ν (cm⁻¹): 3356.5, 3054.6, 1586.0, 1453.7, 1338.1, 1310.2, 1196.5, 1066.0, 957.9, 861.0, 807.0, 732.4, 598.2; HRMS (ESI): calcd for C₁₈H₁₄NS⁺ [M + H]⁺ 276.0841; found 276.0839.

4-((1*H*-indol-5-yl)thio)benzonitrile (3ii)




81% (40.4 mg); white solid; mp 141–143 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.46 (s, 1H), 7.89 – 7.88 (m, 1H), 7.47 (d, *J* = 8.4 Hz, 1H), 7.42 – 7.38 (m, 2H), 7.33 – 7.29 (m, 2H), 7.08 – 7.04 (m, 2H), 6.60 – 6.58 (m, 1H). ¹³C NMR (101 MHz, CDCl₃) δ 148.3, 136.2, 132.1, 129.2, 128.9, 128.8, 125.8, 125.6, 119.3, 119.1, 112.7, 107.4, 102.9. IR (neat) ν (cm⁻¹): 3421.7, 2227.1, 1587.8, 1483.5, 1401.5, 1310.2, 1243.1, 1179.7, 1079.1, 887.1, 807.0, 736.1, 616.9, 581.5; HRMS (ESI): calcd for C₁₅H₁₁N₂S⁺ [M + H]⁺ 251.0637; found 251.0636.

5-((2,3-dihydrobenzofuran-5-yl)thio)-1*H*-indole (3jj)



81% (43.2 mg); white solid; mp 72–74 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.19 (s, 1H), 7.69 – 7.68 (m, 1H), 7.32 – 7.29 (m, 1H), 7.25 – 7.14 (m, 4H), 6.70 (d, *J* = 8.2 Hz, 1H), 6.50 – 6.48 (m, 1H), 4.54 (t, *J* = 8.7 Hz, 2H), 3.12 (t, *J* = 8.7 Hz, 2H). ¹³C NMR (101 MHz, CDCl₃) δ 159.4, 135.0, 131.3, 128.6, 128.2, 128.1, 127.9, 126.7, 126.0, 124.9, 124.3, 111.8, 109.8, 102.5, 71.4, 29.6. IR (neat) ν (cm⁻¹): 3352.7, 2968.8, 2892.4, 1584.1, 1477.9, 1313.9, 1237.5, 1164.8, 1107.0, 877.8, 808.8, 725.0, 609.4; HRMS (ESI): calcd for C₁₆H₁₄NOS⁺ [M + H]⁺ 268.0791; found 268.0792.


5-(mesitylthio)-1*H*-indole (3kk)



82% (44.1 mg); white solid; mp 115–116 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.01 (s, 1H), 7.21 – 7.18 (m, 2H), 7.11 – 7.10 (m, 1H), 6.99 (s, 2H), 6.90 (dd, *J* = 8.4, 1.8 Hz, 1H), 6.37 – 6.36 (m, 1H), 2.42 (s, 6H), 2.31 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 143.5, 138.6, 134.0, 129.2, 129.0, 128.7, 128.2, 124.6, 121.5, 118.4, 111.5, 102.1, 21.9, 21.1. IR (neat) ν (cm⁻¹): 3371.4, 2916.6, 1569.2, 1451.8, 1418.3, 1312.0, 1243.1, 1053.0,


866.6, 799.5, 760.4, 736.1, 598.2; HRMS (ESI): calcd for $C_{17}H_{18}NS^+$ [M + H]⁺ 268.1154; found 268.1156.

5-((2,4,6-triisopropylphenyl)thio)-1*H*-indole (3ll)




78% (54.5 mg); white solid; mp 94–95 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.96 (s, 1H), 7.19 – 7.17 (m, 2H), 7.11 (s, 2H), 7.08 – 7.07 (m, 1H), 6.86 (dd, *J* = 8.6, 1.6 Hz, 1H), 6.37 – 6.35 (m, 1H), 3.87 – 3.79 (m, 2H), 2.98 – 2.90 (m, 1H), 1.30 (d, *J* = 6.9 Hz, 6H), 1.13 (d, *J* = 6.9 Hz, 12H). ¹³C NMR (101 MHz, CDCl₃) δ 153.6, 150.2, 133.8, 130.1, 128.6, 126.5, 124.6, 122.1, 120.9, 117.8, 111.4, 102.0, 34.3, 31.6, 24.3, 23.9. IR (neat) ν (cm^{−1}): 3404.9, 2957.6, 2866.3, 1597.2, 1565.5, 1449.9, 1306.4, 1099.6, 1056.7, 937.4, 874.1, 805.1, 721.2; HRMS (ESI): calcd for C₂₃H₂₉NSNa⁺ [M + Na]⁺ 352.2093; found 352.2092.

5-(benzo[*b*]thiophen-3-ylthio)-1*H*-indole (3mm)



80% (45.0 mg); colorless liquid; ¹H NMR (500 MHz, CDCl₃) δ 8.13 (s, 1H), 7.92 – 7.84 (m, 2H), 7.73 – 7.72 (m, 1H), 7.40 (s, 1H), 7.38 – 7.35 (m, 2H), 7.30 – 7.28 (m, 1H), 7.25 – 7.23 (m, 1H), 7.18 – 7.17 (m, 1H), 6.48 – 6.47 (m, 1H). ¹³C NMR (126 MHz, CDCl₃) δ 140.0, 138.6, 135.0, 128.7, 127.8, 127.5, 125.0, 125.0, 124.7, 124.6, 124.4, 123.4, 122.9, 122.8, 111.8, 102.5. IR (neat) ν (cm^{−1}): 3418.0, 3095.6, 3056.4, 1567.3, 1451.8, 1410.8, 1306.4, 1252.4, 1196.5, 1060.4, 1017.6, 954.2, 889.0; HRMS (ESI): calcd for C₁₆H₁₂NS₂⁺ [M + H]⁺ 282.0406; found 282.0404.


methyl 3-((1*H*-indol-5-yl)thio)thiophene-2-carboxylate (3nn)




61% (35.3 mg); colorless liquid; ¹H NMR (400 MHz, CDCl₃) δ 8.44 (s, 1H), 7.97 – 7.91 (m, 1H), 7.47 – 7.38 (m, 2H), 7.30 – 7.28 (m, 1H), 7.20 (d, *J* = 5.3 Hz, 1H), 6.59 – 6.57 (m, 1H), 6.25 (d, *J* = 5.3 Hz, 1H), 3.93 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 162.8, 148.1, 136.1, 130.2, 129.0, 128.9, 128.5, 128.1, 125.4, 121.9, 119.8, 112.3, 103.0, 52.0. IR (neat) ν (cm^{−1}): 3254.0, 2950.2, 1656.8, 1492.8, 1436.9, 1452.2, 1349.3,

1250.5, 1190.9, 1075.3, 889.0; HRMS (ESI): calcd for $C_{14}H_{12}NO_2S_2^+$ [M + H]⁺ 290.0304; found 290.0303.


benzyl(*p*-tolyl)sulfane (5a**)**

 73% (31.4 mg); white solid; mp 35–36 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.29 – 7.24 (m, 3H), 7.24 – 7.19 (m, 3H), 7.07 – 7.04 (m, 2H), 4.06 (s, 2H), 2.30 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 137.8, 136.5, 132.4, 130.7, 129.6, 128.8, 128.4, 127.0, 39.8, 21.0. IR (neat) ν (cm^{−1}): 3062.0, 3028.5, 2920.4, 2864.5, 1599.0, 1492.8, 1451.8, 1235.6, 1090.2, 799.5, 695.1, 564.7; HRMS (EI): calcd for C₁₄H₁₄S [M] 214.0816; found 214.0811.


3-(*p*-tolylthio)propyl benzoate (5b**)**

 81% (42.6 mg); colorless liquid; ¹H NMR (400 MHz, CDCl₃) δ 8.03 – 8.01 (m, 2H), 7.58 – 7.53 (m, 1H), 7.46 – 7.41 (m, 2H), 7.30 – 7.27 (m, 2H), 7.11 – 7.08 (m, 2H), 4.42 (t, J = 6.2 Hz, 2H), 3.03 (t, J = 7.2 Hz, 2H), 2.31 (s, 3H), 2.10 – 2.03 (m, 2H). ¹³C NMR (101 MHz, CDCl₃) δ 166.4, 136.4, 132.9, 132.0, 130.4, 130.2, 129.7, 129.5, 128.3, 63.3, 31.1, 28.5, 21.0. IR (neat) ν (cm^{−1}): 3062.0, 2955.8, 2920.4, 1716.4, 1600.9, 1492.8, 1449.9, 1313.9, 1267.3, 1176.0, 1110.7, 1026.9, 803.2, 708.2; HRMS (ESI): calcd for C₁₇H₁₈O₂Na⁺ [M + Na]⁺ 309.0920; found 309.0917.


phenyl(3-(*p*-tolylthio)propyl)sulfane (5c**)**

 86% (47.4 mg); colorless liquid; ¹H NMR (400 MHz, CDCl₃) δ 7.32 – 7.26 (m, 2H), 7.26 – 7.22 (m, 3H), 7.19 – 7.14 (m, 1H), 7.09 – 7.06 (m, 2H), 3.04 – 2.97 (m, 4H), 2.31 (s, 3H), 1.95 – 1.88 (m, 2H). ¹³C NMR (101 MHz, CDCl₃) δ 136.3, 136.1, 132.1, 130.3, 129.7, 129.3, 128.9, 126.0, 33.2, 32.3, 28.3, 21.0. IR (neat) ν (cm^{−1}): 3054.6, 3017.3, 2918.5, 2855.1, 1582.3, 1492.8, 1436.9, 1246.8, 1090.2, 1025.0, 801.4, 736.1, 689.6, 542.3; HRMS (ESI): calcd for C₁₆H₁₈S₂Na⁺ [M + Na]⁺ 297.0742; found 297.0745.


(3-phenylpropyl)(*p*-tolyl)sulfane (5d**)**


 83% (40.3 mg); colorless liquid; ^1H NMR (500 MHz, CDCl_3) δ 7.28 – 7.21 (m, 4H), 7.20 – 7.15 (m, 3H), 7.09 – 7.06 (m, 2H), 2.92 – 2.82 (m, 2H), 2.78 – 2.69 (m, 2H), 2.31 (s, 3H), 1.96 – 1.90 (m, 2H). ^{13}C NMR (101 MHz, CDCl_3) δ 141.4, 136.0, 132.6, 130.0, 129.6, 128.5, 128.4, 125.9, 34.6, 33.6, 30.7, 21.0. IR (neat) ν (cm^{-1}): 3062.0, 3024.7, 2920.4, 2855.1, 1602.8, 1492.8, 1451.8, 1092.1, 799.5, 743.6, 698.9, 566.6; HRMS (ESI): calcd for $\text{C}_{16}\text{H}_{19}\text{S}^+$ $[\text{M} + \text{H}]^+$ 243.1202; found 243.1203.


tert-butyldimethyl(3-(*p*-tolylthio)propoxy)silane (5e)


 75% (44.3 mg); colorless liquid; ^1H NMR (500 MHz, CDCl_3) δ 7.29 – 7.27 (m, 2H), 7.13 – 7.11 (m, 2H), 3.73 (t, $J = 6.0$ Hz, 2H), 3.06 – 2.92 (m, 2H), 2.34 (s, 3H), 1.87 – 1.81 (m, 2H), 0.92 (s, 9H), 0.08 (s, 6H). ^{13}C NMR (126 MHz, CDCl_3) δ 135.8, 132.8, 129.7, 129.6, 61.4, 32.2, 30.6, 25.9, 21.0, 18.3, -5.4. IR (neat) ν (cm^{-1}): 2953.9, 2927.8, 2857.0, 1492.8, 1254.2, 1092.1, 948.6, 833.1, 803.2, 773.4, 661.6, 542.3; HRMS (ESI): calcd for $\text{C}_{16}\text{H}_{29}\text{OSSi}^+$ $[\text{M} + \text{H}]^+$ 297.1703; found 297.1708.

hex-5-en-1-yl(*p*-tolyl)sulfane (5f)



 84% (34.9 mg); colorless liquid; ^1H NMR (400 MHz, CDCl_3) δ 7.25 – 7.23 (m, 2H), 7.10 – 7.07 (m, 2H), 5.84 – 5.72 (m, 1H), 5.02 – 4.92 (m, 2H), 2.90 – 2.84 (m, 2H), 2.31 (s, 3H), 2.09 – 2.02 (m, 2H), 1.68 – 1.59 (m, 2H), 1.55 – 1.46 (m, 2H). ^{13}C NMR (101 MHz, CDCl_3) δ 138.4, 135.9, 133.0, 129.8, 129.6, 114.7, 34.2, 33.2, 28.7, 28.0, 21.0. IR (neat) ν (cm^{-1}): 3075.1, 2924.1, 2855.1, 1640.0, 1492.8, 1436.9, 1209.5, 1092.1, 991.5, 909.5, 799.5, 631.8; HRMS (ESI): calcd for $\text{C}_{13}\text{H}_{19}\text{S}^+$ $[\text{M} + \text{H}]^+$ 207.1202; found 207.1202.

4,4,5,5-tetramethyl-2-(*p*-tolylthio)propyl)-1,3,2-dioxaborolane (5g)



 57% (33.2 mg); colorless liquid; ^1H NMR (500 MHz, CDCl_3) δ 7.26 – 7.24 (m, 2H), 7.08 – 7.07 (m, 2H), 2.90 – 2.87 (m, 2H), 2.31 (s, 3H), 1.77 – 1.71 (m, 2H), 1.24 (s, 12H), 0.90 (t, $J = 7.7$ Hz, 2H). ^{13}C NMR (126 MHz, CDCl_3) δ 135.5, 133.2, 129.5, 129.4, 83.0, 36.3, 24.8, 24.0, 20.9.

IR (neat) ν (cm⁻¹): 2978.1, 2924.1, 1492.8, 1369.8, 1313.9, 1224.4, 1142.4, 1092.1, 967.2, 848.0, 801.4, 672.8; HRMS (ESI): calcd for C₁₆H₂₅BO₂SNa⁺ [M + Na]⁺ 315.1561; found 315.1559.


2-(2-(*p*-tolylthio)ethyl)-1,3-dioxolane (5h)

 76% (34.0 mg); colorless liquid; ¹H NMR (500 MHz, CDCl₃) δ 7.27 – 7.24 (m, 2H), 7.10 – 7.08 (m, 2H), 4.97 (t, *J* = 4.5 Hz, 1H), 3.99 – 3.92 (m, 2H), 3.88 – 3.81 (m, 2H), 2.99 – 2.96 (m, 2H), 2.31 (s, 3H), 1.99 – 1.95 (m, 2H). ¹³C NMR (101 MHz, CDCl₃) δ 136.1, 132.3, 130.0, 129.7, 103.1, 64.9, 33.6, 28.6, 21.0. IR (neat) ν (cm⁻¹): 2950.2, 2879.4, 1492.8, 1436.9, 1397.8, 1211.4, 1129.4, 1015.7, 943.0, 875.9, 803.2, 697.0; HRMS (ESI): calcd for C₁₂H₁₆O₂SNa⁺ [M + Na]⁺ 247.0763; found 247.0767.


benzyl 2-(*p*-tolylthio)acetate (5i)

 72% (39.2 mg); colorless liquid; ¹H NMR (500 MHz, CDCl₃) δ 7.37 – 7.25 (m, 7H), 7.08 – 7.05 (m, 2H), 5.12 (s, 2H), 3.61 (s, 2H), 2.31 (s, 3H). ¹³C NMR (126 MHz, CDCl₃) δ 169.6, 137.4, 135.4, 131.1, 130.9, 129.8, 128.5, 128.3, 128.2, 67.1, 37.4, 21.0. IR (neat) ν (cm⁻¹): 3065.7, 3032.2, 2553.9, 2922.2, 1731.3, 1492.8, 1407.1, 1265.4, 1120.1, 971.0, 805.1, 736.1, 695.1, 575.9; HRMS (ESI): calcd for C₁₆H₁₆O₂SNa⁺ [M + Na]⁺ 295.0763; found 295.0764.


ethyl 6-(*p*-tolylthio)hexanoate (5j)

 93% (49.6 mg); colorless liquid; ¹H NMR (500 MHz, CDCl₃) δ 7.26 – 7.22 (m, 2H), 7.10 – 7.08 (m, 2H), 4.12 (q, *J* = 7.1 Hz, 2H), 2.90 – 2.82 (m, 2H), 2.31 (s, 3H), 2.28 (t, *J* = 7.5 Hz, 2H), 1.66 – 1.59 (m, 4H), 1.48 – 1.41 (m, 2H), 1.25 (t, *J* = 7.1 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 173.6, 135.9, 132.8, 129.9, 129.6, 60.2, 34.1, 28.8, 28.2, 24.5, 20.9, 14.2. IR (neat) ν (cm⁻¹): 2980.0, 2929.7, 2860.7, 1731.3, 1492.8, 1459.3, 1371.7, 1254.2, 1177.8, 1092.1, 1017.6, 801.4; HRMS (ESI): calcd for C₁₅H₂₂O₂SNa⁺ [M + Na]⁺ 289.1233; found 289.1237.


(2-phenoxyethyl)(*p*-tolyl)sulfane (5k**)**

 81% (39.6 mg); white solid; mp 39–41 °C; ^1H NMR (500 MHz, CDCl_3) δ 7.33 – 7.32 (m, 2H), 7.27 – 7.23 (m, 2H), 7.12 – 7.10 (m, 2H), 6.95 – 6.92 (m, 1H), 6.86 – 6.83 (m, 2H), 4.11 (t, J = 7.1 Hz, 2H), 3.23 (t, J = 7.1 Hz, 2H), 2.32 (s, 3H). ^{13}C NMR (126 MHz, CDCl_3) δ 158.4, 136.8, 131.5, 130.7, 129.8, 129.4, 121.0, 114.5, 66.5, 33.5, 21.0. IR (neat) ν (cm $^{-1}$): 3062.0, 3043.4, 2918.5, 2868.2, 2728.4, 1599.0, 1489.1, 1422.0, 1377.3, 1239.3, 1170.4, 1080.9, 1012.0, 879.7, 799.5, 747.3, 687.7; HRMS (ESI): calcd for $\text{C}_{15}\text{H}_{16}\text{OSNa}^+ [M + \text{Na}]^+$ 267.0814; found 267.0827.

1-phenyl-2-(*p*-tolylthio)propan-1-one (5l**)**

 $\text{Ni}(\text{PCy}_3)_2\text{Cl}_2$ was used for the preparation of **5l** in the absence of dtbbpy. 27% (13.9 mg); colorless liquid; ^1H NMR (400 MHz, CDCl_3) δ 7.98 – 7.94 (m, 2H), 7.58 – 7.53 (m, 1H), 7.47 – 7.43 (m, 2H), 7.24 – 7.22 (m, 2H), 7.09 – 7.07 (m, 2H), 4.56 (q, J = 6.8 Hz, 1H), 2.32 (s, 3H), 1.50 (d, J = 6.8 Hz, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ 196.1, 139.0, 135.8, 135.2, 133.0, 129.7, 128.6, 128.5, 127.7, 46.1, 21.2, 16.8. IR (neat) ν (cm $^{-1}$): 2972.2, 2925.3, 1677.3, 1595.5, 1491.1, 1447.3, 1371.2, 1329.2, 1230.2, 1176.6, 1000.7, 949.0, 811.1, 798.1, 716.1, 686.2. HRMS (ESI): calcd for $\text{C}_{16}\text{H}_{16}\text{NaOS}^+ [M + \text{Na}]^+$ 279.0814; found 279.0817.

(E)-styryl(*p*-tolyl)sulfane (7a**)**

 68% (38.9 mg); colorless liquid; ^1H NMR (400 MHz, CDCl_3) δ 7.53 – 7.26 (m, 6H), 7.23 – 7.13 (m, 3H), 6.87 – 6.43 (m, 2H), 2.35 – 2.30 (m, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ 137.4*, 137.3, 136.6, 136.5*, 131.1*, 130.6, 130.5*, 130.5, 129.9, 129.9*, 128.7*, 128.6, 128.3*, 127.4, 127.0*, 127.0, 126.5*, 126.4*, 125.9, 124.4, 21.1. IR (neat) ν (cm $^{-1}$): 3056.4, 3021.0, 2920.4, 2862.6, 1597.2, 1490.9, 1090.2, 937.4, 803.2, 736.1, 689.6. HRMS (EI): calcd for $\text{C}_{15}\text{H}_{14}\text{S} [M]$ 226.0816; found 226.0811.

(1*H*-inden-2-yl)(*p*-tolyl)sulfane (7b**)**

Me 92% (43.7 mg); white solid; mp 51-52 °C; ¹H NMR (500 MHz, CDCl₃) δ 7.41 – 7.38 (m, 2H), 7.30 – 7.28 (m, 1H), 7.20 – 7.15 (m, 4H), 7.10 – 7.06 (m, 1H), 6.56 (s, 1H), 3.42 (s, 2H), 2.36 (s, 3H). ¹³C NMR (126 MHz, CDCl₃) δ 144.7, 143.3, 143.0, 138.2, 132.9, 130.0, 129.8, 129.1, 126.5, 124.0, 123.2, 119.7, 41.9, 21.2. IR (neat) v (cm⁻¹): 3065.7, 3021.0, 2918.5, 2864.5, 1604.6, 1537.5, 1490.9, 1455.5, 1390.3, 1269.2, 1015.7, 807.0, 749.2, 713.8; HRMS (ESI): calcd for C₁₆H₁₅S⁺ [M + H]⁺ 239.0889; found 239.0890.

triisopropyl((*p*-tolylthio)ethynyl)silane (**9a**)

TIPS 71% (43.4 mg); colorless liquid; ¹H NMR (400 MHz, CDCl₃) δ 7.35 – 7.31 (m, 2H), 7.16 – 7.13 (m, 2H), 2.33 (s, 3H), 1.13 – 1.10 (m, 21H). ¹³C NMR (101 MHz, CDCl₃) δ 136.3, 129.9, 129.1, 126.2, 102.5, 91.8, 20.9, 18.6, 11.4. IR (neat) v (cm⁻¹): 2942.7, 2864.5, 2091.0, 1490.9, 1459.3, 1082.8, 995.2, 859.2, 801.4, 676.5, 590.8; HRMS (ESI): calcd for C₁₈H₂₉SSi⁺ [M + H]⁺ 305.1754; found 305.1751.

triisopropyl(((4-(trifluoromethoxy)phenyl)thio)ethynyl)silane (**9b**)

TIPS 39% (28.9 mg); colorless liquid; ¹H NMR (400 MHz, CDCl₃) δ 7.47 – 7.43 (m, 2H), 7.21 – 7.18 (m, 2H), 1.32 – 0.91 (m, 21H). ¹³C NMR (101 MHz, CDCl₃) δ 147.8, 131.7, 127.2, 121.9, 120.4 (q, *J* = 257.4 Hz), 104.1, 90.3, 18.6, 11.3. IR (neat) v (cm⁻¹): 2944.6, 2866.3, 2092.9, 1489.1, 1463.0, 1254.2, 1205.8, 1162.9, 1080.9, 1015.7, 918.8, 857.3, 659.7, 590.8; HRMS (ESI): calcd for C₁₈H₂₆F₃OSSi⁺ [M + H]⁺ 375.1420; found 375.1422.

(((4-(*tert*-butyl)phenyl)thio)ethynyl)triisopropylsilane (**9c**)

tBu 50% (34.8 mg); colorless liquid; ¹H NMR (400 MHz, CDCl₃) δ 7.36 (s, 1H), 1.31 (s, 3H), 1.19 – 1.00 (m, 6H). ¹³C NMR (101 MHz, CDCl₃) δ 149.6, 129.1, 126.3, 125.8, 102.7, 91.5, 34.5, 31.3, 18.6, 11.4. IR (neat) v (cm⁻¹): 2942.7, 2864.5, 2091.0, 1459.3, 1364.2, 1116.3, 1012.0, 859.2, 821.9, 736.1, 676.5, 592.6; HRMS (ESI): calcd for C₂₁H₃₄SSiNa⁺ [M + Na]⁺ 369.2043; found 369.2045.

((3-chloro-4-fluorophenyl)thio)ethynyltriisopropylsilane (9d)

68% (46.4 mg); colorless liquid; ^1H NMR (400 MHz, CDCl_3) δ 7.53 (dd, $J = 6.6, 2.4$ Hz, 1H), 7.27 – 7.23 (m, 1H), 7.11 (t, $J = 8.6$ Hz, 1H), 1.22 – 0.94 (m, 21H). ^{13}C NMR (101 MHz, CDCl_3) δ 156.9 (d, $J = 248.9$ Hz), 129.4 (d, $J = 3.8$ Hz), 128.1, 125.7 (d, $J = 7.2$ Hz), 122.2 (d, $J = 18.7$ Hz), 117.2 (d, $J = 22.2$ Hz), 104.5, 90.2, 18.6, 11.3. IR (neat) ν (cm^{-1}): 2942.7, 2864.5, 2092.9, 1479.8, 1261.7, 1094.0, 1056.7, 995.2, 857.3, 810.7, 713.8, 676.5, 592.6; HRMS (EI): calcd for $\text{C}_{17}\text{H}_{24}\text{ClFSSi}$ [M] 342.1041; found 342.1043.

((3-chlorophenyl)thio)ethynyltriisopropylsilane (9e)

87% (56.6 mg); colorless liquid; ^1H NMR (400 MHz, CDCl_3) δ 7.50 – 7.49 (m, 1H), 7.27 – 7.24 (m, 2H), 7.18 (dt, $J = 7.0, 1.9$ Hz, 1H), 1.16 – 1.08 (m, 21H). ^{13}C NMR (101 MHz, CDCl_3) δ 135.3, 135.0, 130.0, 126.5, 125.7, 123.9, 104.8, 89.8, 18.6, 11.3. IR (neat) ν (cm^{-1}): 2942.7, 2864.5, 2092.9, 1576.7, 1459.3, 1408.9, 1071.6, 995.2, 857.3, 769.7, 672.8, 590.8; HRMS (ESI): calcd for $\text{C}_{17}\text{H}_{26}\text{ClSSi}^+$ [M + H]⁺ 325.1208; found 325.1205.

triisopropyl((naphthalen-2-ylthio)ethynyl)silane (9f)


51% (34.9 mg); colorless liquid; ^1H NMR (400 MHz, CDCl_3) δ 7.95 (s, 1H), 7.79 (d, $J = 8.6$ Hz, 2H), 7.72 (d, $J = 8.0$ Hz, 1H), 7.50 – 7.41 (m, 3H), 1.22 – 1.09 (m, 21H). ^{13}C NMR (101 MHz, CDCl_3) δ 133.8, 132.0, 130.2, 128.8, 127.8, 127.0, 126.8, 125.9, 124.3, 123.9, 103.6, 91.2, 18.7, 11.4. IR (neat) ν (cm^{-1}): 2942.7, 2864.5, 2091.0, 1589.7, 1459.3, 1133.1, 1064.2, 995.2, 881.5, 849.8, 807.0, 739.9, 676.5, 590.8; HRMS (ESI): calcd for $\text{C}_{21}\text{H}_{28}\text{SSiNa}^+$ [M + Na]⁺ 363.1573; found 363.1571.

4-(((triisopropylsilyl)ethynyl)thio)benzonitrile (9g)


61% (38.2 mg); colorless liquid; ^1H NMR (400 MHz, CDCl_3) δ 7.62 – 7.59 (m, 2H), 7.53 – 7.51 (m, 2H), 1.29 – 0.89 (m, 21H). ^{13}C NMR (101 MHz, CDCl_3) δ 140.4, 132.5, 125.9, 118.4, 109.7, 106.4, 88.2, 18.6, 11.2. IR (neat) ν (cm^{-1}): 2942.7, 2864.5, 2228.9, 2094.8, 1591.6, 1459.3,

1401.5, 1079.1, 995.2, 881.5, 855.4, 821.9, 676.5, 590.8, 542.3; HRMS (ESI): calcd for $C_{18}H_{25}NSSiNa^+$ [M + Na]⁺ 338.1369; found 338.1368.

((2,3-dihydrobenzofuran-5-yl)thio)ethynyl)triisopropylsilane (9h)


 48% (31.9 mg); colorless liquid; ¹H NMR (400 MHz, CDCl₃) δ 7.32 – 7.31 (m, 1H), 7.20 – 7.17 (m, 1H), 6.75 (d, *J* = 8.4 Hz, 1H), 4.58 (t, *J* = 8.7 Hz, 2H), 3.19 (t, *J* = 8.7 Hz, 2H), 1.13 – 1.04 (m, 21H). ¹³C NMR (101 MHz, CDCl₃) δ 159.6, 128.6, 127.3, 124.2, 122.4, 110.1, 101.2, 93.2, 71.5, 29.6, 18.6, 11.4. IR (neat) ν (cm⁻¹): 2942.7, 2864.5, 2089.2, 1466.7, 1231.9, 982.2, 943.0, 855.4, 810.7, 676.5, 594.5; HRMS (ESI): calcd for $C_{19}H_{29}OSSi^+$ [M + H]⁺ 333.1703; found 333.1707.

((benzo[b]thiophen-3-ylthio)ethynyl)triisopropylsilane (9i)

 64% (44.3 mg); colorless liquid; ¹H NMR (500 MHz, CDCl₃) δ 7.91 – 7.84 (m, 2H), 7.53 (s, 1H), 7.44 – 7.37 (m, 2H), 1.07 (s, 21H). ¹³C NMR (126 MHz, CDCl₃) δ 134.0, 137.0, 125.0, 124.8, 124.5, 122.9, 122.2, 100.6, 91.1, 18.6, 11.3. IR (neat) ν (cm⁻¹): 2942.7, 2864.5, 2092.9, 1459.3, 1422.0, 1315.8, 1256.1, 1062.3, 995.2, 881.5; HRMS (ESI): calcd for $C_{19}H_{27}S_2Si^+$ [M + H]⁺ 347.1318; found 347.1317.


(3aS,5S,6R,6aS)-5-((S)-2,2-dimethyl-1,3-dioxolan-4-yl)-2,2-

dimethyltetrahydrofuro[2,3-*d*][1,3]dioxol-6-yl 2-(*p*-tolylthio)acetate (10a)

 52% (43.4 mg); white solid; mp 77–79 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.36 – 7.33 (m, 2H), 7.14 – 7.11 (m, 2H), 5.69 (d, *J* = 3.7 Hz, 1H), 5.23 (d, *J* = 2.3 Hz, 1H), 4.22 (d, *J* = 3.7 Hz, 1H), 4.18 – 4.12 (m, 2H), 4.06 – 3.96 (m, 2H), 3.65 – 3.56 (m, 2H), 2.33 (s, 3H), 1.49 (s, 3H), 1.40 (s, 3H), 1.29 (s, 3H), 1.27 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 168.5, 137.7, 131.3, 130.6, 129.9, 112.3, 109.4, 105.0, 83.1, 79.7, 76.8, 72.2, 67.2, 37.3, 26.8, 26.6, 26.1, 25.2, 21.1. IR (neat) ν (cm⁻¹): 2991.2, 2922.2, 1735.1, 1492.8, 1371.7, 1211.4, 1123.8,


1079.1, 1015.7, 941.2, 810.7, 643.0; HRMS (ESI): calcd for $C_{21}H_{29}O_7S^+$ [M + H]⁺ 425.1629; found 425.1631.

(R)-2,5,7,8-tetramethyl-2-((4*R*,8*R*)-4,8,12-trimethyltridecyl)chroman-6-yl 2-(*p*-tolylthio)acetate (10b)




¹H NMR (400 MHz, CDCl₃) δ 7.42 – 7.39 (m, 2H), 7.12 – 7.09 (m, 2H), 3.84 (s, 2H), 2.55 (t, *J* = 6.7 Hz, 2H), 2.31 (s, 3H), 2.09 – 1.90 (m, 9H), 1.83 – 1.68 (m, 2H), 1.58 – 1.48 (m, 3H), 1.43 – 1.02 (m, 21H), 0.88 – 0.83 (m, 12H). ¹³C NMR (101 MHz, CDCl₃) δ 168.5, 149.5, 140.3, 137.3, 131.2, 130.7, 129.8, 126.6, 124.9, 123.0, 117.3, 75.0, 39.3, 37.4, 37.3, 37.0, 32.8, 32.7, 27.9, 24.8, 24.4, 22.7, 22.6, 21.0, 21.0, 20.5, 19.7, 19.6, 12.8, 12.0, 11.8. IR (neat) ν (cm⁻¹): 2924.1, 2866.3, 1751.8, 1459.3, 1377.3, 1241.2, 1105.2, 1064.2, 922.5, 803.2, 736.1; HRMS (ESI): calcd for C₃₈H₅₉O₃S⁺ [M + H]⁺ 595.4179; found 595.4176.

N-(((1*R*,4*aS*,10*aR*)-7-isopropyl-1,4*a*-dimethyl-1,2,3,4,4*a*,9,10,10*a*-octahydrophenanthren-1-yl)methyl)-2-(*p*-tolylthio)acetamide (10c)



1015.7, 909.5, 801.4, 730.6, 620.6; HRMS (ESI): calcd for $C_{29}H_{40}NOS^+$ [M + H]⁺ 450.2825; found 450.2827.

(2R,5S,8R,9S,10S,13S,14S,17S)-2,10,13,17-tetramethyl-3-oxohexadecahydro-1*H*-cyclopenta[*a*]phenanthren-17-yl 2-(*p*-tolylthio)acetate (10d)




tert-butyl 4-(2-iodophenyl)piperazine-1-carboxylate (11)

Boc Under argon, to a suspension of Pd₂(dba)₃ (0.025 mmol, 2.5 mol%), BINAP (0.075 mmol, 7.5 mol%), *tert*-butyl piperazine-1-carboxylate (1.0 mmol, 1.0 equiv) and *t*-BuONa (1.2 mmol, 1.2 equiv) in toluene (2.5 mL) was added 1,2-diiodobenzene (2.0 mmol, 2.0 equiv) at room temperature. After that, the reaction mixture was stirred at 80 °C for 24 h. Then, distilled water (40 mL) was added and the aqueous layer was extracted with Et₂O (3 × 15mL). The combined organic layers were dried over Na₂SO₄, filtered and concentrated. The product was purified by flash column chromatography on silica gel with *n*-pentane/ethyl acetate as eluent to give the corresponding product **9** in 40% yield; light yellow oil; ¹H NMR (500 MHz, CDCl₃) δ 7.85 (dd, *J* = 7.9, 1.5 Hz, 1H), 7.33 – 7.29 (m, 1H), 7.00 (dd, *J* = 8.0, 1.5 Hz, 1H), 6.83 – 6.79 (m, 1H), 3.62 (s, 4H), 2.92 (s, 4H), 1.49 (s, 9H). ¹³C NMR (126 MHz, CDCl₃) δ 154.8, 153.1, 140.0, 129.2, 125.6, 121.0, 98.3, 79.7, 52.2, 44.5, 28.4. IR (neat) v (cm^{−1}): 3054.6, 2974.4, 2929.7, 2860.7, 2816.0,


1686.6, 1578.5, 1468.6, 1412.7, 1364.2, 1332.5, 1244.9, 1164.8, 1120.1, 1032.5, 998.9, 862.9, 758.5; HRMS (ESI): calcd for $C_{15}H_{22}IN_2O_2^+$ [M + H]⁺ 389.0720; found 389.0718.

tert-butyl 4-((2,4-dimethylphenyl)thio)phenyl)piperazine-1-carboxylate (12)




56%; Viscous oil; ¹H NMR (500 MHz, CDCl₃) δ 7.37 (d, *J* = 7.8 Hz, 1H), 7.15 (s, 1H), 7.09 – 7.00 (m, 3H), 6.89 – 6.85 (m, 1H), 6.52 (dd, *J* = 7.9, 1.3 Hz, 1H), 3.62 – 3.60 (m, 4H), 3.02 – 2.99 (m, 4H), 2.36 (s, 3H), 2.32 (s, 3H), 1.49 (s, 9H). ¹³C NMR (126 MHz, CDCl₃) δ 154.9, 148.9, 142.3, 139.2, 136.1, 134.6, 131.6, 127.8, 127.7, 126.2, 125.4, 124.5, 119.8, 79.6, 51.6, 44.7, 28.4, 21.2, 20.6. This compound has been previously reported in the literature.²

1-(2-((2,4-dimethylphenyl)thio)phenyl)piperazine (13)



A glass vial was charged with N-Boc vortioxetine 10 (79.7 mg, 0.2 mmol) and a magnetic stirrer. Dry CH₂Cl₂ (0.5 mL) and trifluoroacetic acid (0.5 mL) were added and the solution was stirred for 1h at room temperature. The solvent was removed, the residue was dissolved in CH₂Cl₂ (20 mL) and extracted with sat. NaHCO₃ aq (20 mL). The aqueous layer was extracted with CH₂Cl₂ (2 x 20 mL). The organic layers were combined, dried over anhydrous Na₂SO₄ and filtered. The solvent was removed in vacuo to afford vortioxetine (54.1 mg, 90%). ¹H NMR (500 MHz, CDCl₃) δ 7.38 (d, *J* = 7.8 Hz, 1H), 7.15 (s, 1H), 7.10 – 7.01 (m, 3H), 6.88 – 6.84 (m, 1H), 6.52 – 6.50 (m, 1H), 3.09 – 3.06 (m, 8H), 2.36 (s, 3H), 2.32 (s, 3H). ¹³C NMR (126 MHz, CDCl₃) δ 149.5, 142.4, 139.2, 136.2, 134.6, 131.6, 127.9, 127.7, 126.1, 125.4, 124.3, 119.8, 52.8, 46.3, 21.2, 20.6. This compound has been previously reported in the literature.³


1-methoxy-4-tosylbenzene (15)



¹H NMR (500 MHz, CDCl₃) δ 7.87 – 7.84 (m, 2H), 7.80 – 7.78 (m, 2H), 7.28 – 7.26 (m, 2H), 6.96 – 6.93 (m, 2H), 3.83 (s, 3H), 2.38 (s, 3H). ¹³C NMR (126 MHz, CDCl₃) δ

163.2, 143.7, 139.4, 133.5, 129.8, 129.6, 127.3, 114.4, 55.6, 21.5. This compound has been previously reported in the literature.⁴


1,2-dimethyl-1*H*-benzo[*d*]imidazole (16)





¹H NMR (500 MHz, CDCl₃) δ 7.72 – 7.69 (m, 1H), 7.32 – 7.23 (m, 3H), 3.75 (s, 3H), 2.63 (s, 3H). ¹³C NMR (126 MHz, CDCl₃) δ 151.8, 142.5, 135.8, 121.9, 121.8, 119.0, 108.8, 29.8, 13.8. This compound has been previously reported in the literature.⁵

VII. NMR Spectra for Compounds


NMR Spectra of product **1a**:




NMR Spectra of product **1b**:




NMR Spectra of product **1c**:




NMR Spectra of product **1d**:




NMR Spectra of product **1e**:







NMR Spectra of product **1f**:







NMR Spectra of product **1g**:





NMR Spectra of product **1h**:




NMR Spectra of product **1i**:






NMR Spectra of product **1j**:




NMR Spectra of product **1k**:




NMR Spectra of product **1l**:





NMR Spectra of product **1m**:





NMR Spectra of product **1n**:




NMR Spectra of product **3a**:




NMR Spectra of product **3b**:




NMR Spectra of product **3c**:





NMR Spectra of product **3d**:




NMR Spectra of product **3e**:





NMR Spectra of product **3f**:





NMR Spectra of product **3g**:





NMR Spectra of product **3h**:




NMR Spectra of product **3i**:





NMR Spectra of product **3j**:




NMR Spectra of product **3k**:





NMR Spectra of product **3l**:




NMR Spectra of product **3m**:




NMR Spectra of product **3n**:





NMR Spectra of product **3o**:




NMR Spectra of product **3p**:




NMR Spectra of product **3q**:





NMR Spectra of product **3r**:







NMR Spectra of product **3s**:




NMR Spectra of product 3t:





NMR Spectra of product **3u**:





NMR Spectra of product **3v**:





NMR Spectra of product **3w**:





NMR Spectra of product **3x**:





NMR Spectra of product 3y:





NMR Spectra of product **3z**:




NMR Spectra of product **3aa**:





NMR Spectra of product **3bb**:




NMR Spectra of product 3cc:





NMR Spectra of product **3dd**:





NMR Spectra of product **3ee**:







NMR Spectra of product **3ff**:





NMR Spectra of product **3gg**:





NMR Spectra of product **3hh**:





NMR Spectra of product 3ii:




NMR Spectra of product 3jj:




NMR Spectra of product **3kk**:







NMR Spectra of product **3II**:





NMR Spectra of product **3mm**:





NMR Spectra of product **3nn**:





NMR Spectra of product **5a**:





NMR Spectra of product **5b**:




NMR Spectra of product **5c**:




NMR Spectra of product **5d**:





NMR Spectra of product **5e**:





NMR Spectra of product **5f**:





NMR Spectra of product **5g**:




NMR Spectra of product **5h**:





NMR Spectra of product **5i**:





NMR Spectra of product **5j**:





NMR Spectra of product **5k**:






NMR Spectra of product **5l**:





NMR Spectra of product 7a:




NMR Spectra of product **7b**:





NMR Spectra of product **9a**:




NMR Spectra of product **9b**:




NMR Spectra of product **9c**:




NMR Spectra of product **9d**:




NMR Spectra of product **9e**:




NMR Spectra of product **9f**:





NMR Spectra of product **9g**:




NMR Spectra of product **9h**:





NMR Spectra of product **9i**:




NMR Spectra of product **10a**:




NMR Spectra of product **10b**:





NMR Spectra of product **10c**:








NMR Spectra of product **10d**:




NMR Spectra of product **11**:




NMR Spectra of product **12**:




NMR Spectra of product **13**:




NMR Spectra of product 14:



NMR Spectra of product **15**:



NMR Spectra of product **16**:



VIII. References

1. (a) Zhao, B. L.; Li, Z. X.; Wu, Y. X.; Wang, Y. D.; Qian, J. S.; Yuan, Y. and Shi, Z. Z. *Angew. Chem. Int. Ed.* **2019**, *58*, 9448–9452; (b) Huihui, K. M. M.; Caputo, J. A.; Melchor, Z.; Olivares, A. M.; Spiewak, A. M.; Johnson, K. A.; DiBenedetto, T. A.; Kim, S.; Ackerman, L. K. G. and Weix, D. J. *J. Am. Chem. Soc.* **2016**, *138*, 5016–5019.
2. Bang-Andersen, B.; Ruhland, T.; Jørgensen, M.; Smith, G.; Frederiksen, K.; Jensen, K. G.; Zhong, H.; Nielsen, S. M.; Hogg, S.; Mørk, A.; Stensbøl, T. B. *J. Med. Chem.* **2011**, *54*, 3206–3221.
3. García-López, J.-A.; Çetin, M.; Greaney, M. F. *Angew. Chem. Int. Ed.* **2015**, *54*, 2156–2159.
4. Yang, H.; Li, Y.; Jiang, M.; Wang, J. and Fu, H. *Chem. Eur. J.* **2011**, *17*, 5652–5660.
5. Zhang, Z.; Sun, Q.; Xia, C. and Sun W.; *Org. Lett.* **2016**, *18*, 6316–6319.